NEXPHORIA
LL-37
Human cathelicidin antimicrobial peptide. Innate immunity and wound healing research.
Purchase Type
Fresh cold-chain delivery every 30 days
For Research Use Only — Not For Human Consumption
This compound is sold exclusively for qualified research purposes. Not approved by the FDA for therapeutic use.
LL-37 is the only member of the cathelicidin family of antimicrobial peptides expressed in humans. It is derived from the C-terminal cleavage of the human cathelicidin hCAP-18 protein by proteinase 3. LL-37 is expressed in neutrophils, epithelial cells, and various immune cell populations, serving as a first-line defense against pathogens at mucosal surfaces and in wound environments.
Complete Your Protocol
Related compounds.
Side-by-Side Analysis
Compare LL-37 with Similar Compounds
View purity, MW, storage, and pricing side by side.
Frequently Bought Together
Complete Your Protocol
Researchers commonly order these compounds together. Convenient multi-compound ordering.
Wellness
This itemLL-37
5mg
$72
Wellness
RecommendedThymosin Alpha-1
5mg
$66
Recovery & Healing
BPC-157
5mg
$50
3 items selected
Uncheck any item to customize your bundle. Discount applied automatically at checkout.
Research Journal
Related Research Articles
Peptide Research for Autoimmune and Chronic Inflammatory Conditions: KPV, Thymosin Alpha-1, LL-37, and BPC-157
A comprehensive research protocol guide covering KPV, Thymosin Alpha-1, LL-37, and BPC-157 for autoimmune and chronic inflammatory research models. Covers receptor pharmacology, published preclinical and clinical data, multi-compound study design, endpoint selection, and critical controls.
LL-37 Antimicrobial & Wound Healing Protocols — Research Design
Practical research protocols for LL-37: wound healing models (EGFR transactivation, M2 polarization), antimicrobial MIC determination, biofilm disruption assays, reconstitution strategies to prevent aggregation, and experimental design controls.
KLW Stack: KPV + LL-37 + Thymosin Alpha-1 Triple Immune Modulation Research Guide
Comprehensive research guide to the KLW triple immune stack covering three orthogonal immune pathways — NF-κB suppression (KPV), innate antimicrobial defense (LL-37), and adaptive T-cell activation (Thymosin Alpha-1). Protocol design, dosing, endpoints, and synergy rationale.
Complete Your Protocol
Immune Research Stack
LL-37's antimicrobial and innate immune signaling complements Thymosin Alpha-1's adaptive immune modulation in comprehensive immune research.
Wellness
LL-37
5mg
$72
Wellness
Thymosin Alpha-1
5mg
$66